Power Transmission Lines and Towers Market worth $25bn by 2024: Global Market Insights Inc.
Ocean View, Delaware, March 16, 2017 (GLOBE NEWSWIRE) — The industry research report “Power Transmission Lines & Towers Market Size, By Product (High Tension (HT), Extra High Tension (EHT), Ultra High Tension (UHT)), By Voltage Level (132 kV, 220 kV, 440 kV, 660 kV, ≥ 765 kV), By Current Level (HVDC, HVAC), Industry Analysis Report,... Read More →
Ársreikningur Félagsbústaða fyrir árið 2016
Meðfylgjandi er ársreikningur vegna ársins 2016 og samantekt.
Columbus A/S Årsrapport 2016
Meddelelse nr. 5/2017 Se vedhæftede Årsrapport 2016.
Sonoma Pharmaceuticals Announces Results from SebuDerm™ Gel Study in Treatment of Seborrheic Dermatitis
Evaluation of SebuDerm (hypochlorous acid) Gel on Mild to Moderate Facial and Scalp Seborrheic Dermatitis Investigator Global Assessment (IGA) Scores Showed a 33% Improvement at Day 14 and a 52% Improvement at Day 28 Clinical Poster being Presented at the 13th Annual Maui Dermatology Conference on March 20-24 PETALUMA, Calif., March 16, 2017 (GLOBE NEWSWIRE)... Read More →
Columbus A/S Annual Report 2016
Release no. 5/2017 See attached Annual Report 2016.
B2Gold Reports 2016 Fourth Quarter and Full-Year Results
VANCOUVER, British Columbia, March 15, 2017 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX:BTO) (NYSE MKT:BTG) (NSX:B2G) (“B2Gold” or the “Company”) is pleased to announce its operational and financial results for the fourth quarter and year-end December 31, 2016. The Company previously released its gold production and gold revenue for the fourth quarter and full-year 2016, as... Read More →
Merus Named BioCapital Europe 2017 Company of the Year
UTRECHT, The Netherlands, March 16, 2017 (GLOBE NEWSWIRE) — Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has been named BioCapital Europe’s Company of the Year for 2017. In its 15th consecutive year, BioCapital Europe, organized by Life Sciences Partners (LSP), is Europe’s premier life sciences investment... Read More →
USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
MONT-SAINT-GUIBERT, Belgium, March 16, 2017 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell-based therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has decided to reject a new reexamination request of Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary T-cells that... Read More →
Investing in EV Infrastructure: Where the Money Is Going
Last year, 159,139 electric vehicles were sold in the U.S., according to Inside EVs , but that’s just scratching the surface of the industry’s potential. Tesla (NASDAQ: TSLA) plans to build 500,000 EVs in 2018 and General Motors (NYSE: GM) just launched its first big bet on EVs in the Chevy Bolt, which will test... Read More →
Medley Management Inc. Reports Fourth Quarter and Full Year 2016 Results
NEW YORK, March 15, 2017 (GLOBE NEWSWIRE) — Medley Management Inc. (NYSE:MDLY) today reported its financial results for its fourth quarter and year ended December 31, 2016. Highlights Total assets under management were over $5.3 billion as of December 31, 2016 Fee earning assets under management were $3.2 billion as of December 31, 2016 U.S. GAAP net income... Read More →